Dallas—Treatment with pirfenidone (Esbriet, Genentech) reduces seasonal peaks in hospitalizations for respiratory complications in patients with idiopathic pulmonary fibrosis (IPF), according to a new analysis of data from the phase 3 clinical trials that led to the drug’s approval in 2014.
The study, which involved nearly 1,250 patients from the ASCEND and CAPACITY trials, found that 4.4% of patients who received placebo had at least one respiratory hospitalization in